Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
Lung transplant recipients who were given antifungal medications prophylactically to prevent invasive fungal infections had lower rates of mortality.
Although hospitalization risk was higher, mortality, thrombosis, and ICU admission risks were the same in patients with and without liver transplants.
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
As heart transplant recipients may be at increased risk for infection with COVID-19, investigators sought to identify characteristics, treatment, and outcomes of this patient population.
A more accurate prediction for assessing the eligibility of candidates for liver transplantation who received neoadjuvant therapies was shown when mRECIST radiologic response was included within the Metroticket 2.0 framework.
Patients undergoing allogeneic hematopoietic cell transplantation who have greater intestinal microbiota diversity may have a lower risk for mortality.
Donor cytomegalovirus seropositivity at transplantation was associated with an increased risk for thrombotic events post-transplantation.
Among recipients of allogeneic hematopoietic cell transplantation (allo-HCT), gram-negative intestinal colonization is highly predictive of bloodstream infections.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.
